Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 2/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.47 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 5/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.41 |
| ▸ | MAPT | P10636 | 5/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | IDE | P14735 | 1/20 | 0.37 |
| ▸ | TNNI3 | P19429 | 1/20 | 0.37 |
| ▸ | TNNT2 | P45379 | 1/20 | 0.37 |
| ▸ | TNNC1 | P63316 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4099808 | 1.00 | CYP2C9 (0.51) | CYP2C9NPSR1GLO1ALDH1A1CYP2D6 | |
| SCHEMBL5902803 | 1.00 | CYP2C9 (0.51) | CYP2C9NPSR1GLO1ALDH1A1CYP2D6 | |
| SCHEMBL3230226 | 0.88 | CYP2C9 (0.58) | CYP2C9NPSR1GLO1ALDH1A1CYP2D6 | |
| SCHEMBL5015288 | 0.87 | CYP2C9 (0.42) | CYP2C9NPSR1GLO1ALDH1A1CYP2D6 | |
| SCHEMBL2819750 | 0.85 | CYP2C9 (0.49) | CYP2C9NPSR1GLO1ALDH1A1CYP2D6 | |
| SCHEMBL28995580 | 0.85 | CYP2C9 (0.49) | CYP2C9NPSR1GLO1ALDH1A1CYP2D6 | |
| SCHEMBL22548601 | 0.85 | CYP2C9 (0.49) | CYP2C9NPSR1GLO1ALDH1A1CYP2D6 | |
| SCHEMBL18936298 | 0.85 | CYP2C9 (0.49) | CYP2C9NPSR1GLO1ALDH1A1CYP2D6 | |
| SCHEMBL2601721 | 0.85 | CYP2C9 (0.49) | CYP2C9NPSR1GLO1ALDH1A1CYP2D6 | |
| SCHEMBL18936299 | 0.85 | CYP2C9 (0.49) | CYP2C9NPSR1GLO1ALDH1A1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219954-A1 | P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS | ASANA BIOSCIENCES, LLC | 2023-07-13 | — | — | US | disclosed |
| US-11685736-B2 | P2X3 and/or P2X2/3 compounds and methods | ABS DEVELOPMENT 1, INC. (US) | 2023-06-27 | — | — | US | disclosed |
| EP-3083619-B1 | P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS | ASANA BIOSCIENCES LLC (US) | 2021-11-03 | — | — | EP | disclosed |
| US-20200109143-A1 | P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS | ABS DEVELOPMENT 1, INC. | 2020-04-09 | — | — | US | disclosed |
| US-10590127-B2 | P2X3 and/or P2X2/3 compounds and methods | ASANA BIOSCIENCES, LLC (US) | 2020-03-17 | — | — | US | disclosed |
| US-10550102-B2 | Indane and indoline derivatives and the use thereof as soluble guanylate cyclase activators | NOVARTIS AG (CH) | 2020-02-04 | — | — | US | disclosed |
| US-10544145-B2 | P2X3 and/or P2X2/3 compounds and methods | ASANA BIOSCIENCES, LLC (US) | 2020-01-28 | — | — | US | disclosed |
| US-20190248789-A1 | P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS | ABS DEVELOPMENT 1, INC. | 2019-08-15 | — | — | US | disclosed |
| US-10316039-B2 | P2X3 and/or P2X2/3 compounds and methods | ASANA BIOSCIENCES, LLC (US) | 2019-06-11 | — | — | US | disclosed |
| US-20190119254-A1 | INDANE AND INDOLINE DERIVATIVES AND THE USE THEREOF AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2019-04-25 | — | — | US | disclosed |
| EP-1904474-A1 | NEW PYRIDINE ANALOGUES | AstraZeneca AB (SE) | 2008-04-02 | — | — | EP | disclosed |
| EP-1836189-A1 | NOVEL PYRIDINE COMPOUNDS | AstraZeneca AB (SE) | 2007-09-26 | — | — | EP | disclosed |
| WO-2006073361-A9 | NOVEL PYRIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2007-08-02 | — | — | WO | disclosed |
| WO-2007008140-A1 | NEW PYRIDINE ANALOGUES | ASTRAZENECA AB (SE) | 2007-01-18 | — | — | WO | disclosed |
| US-20060241151-A1 | Pyrid-2-one derivatives and methods of use | AMGEN, INC. (US) | 2006-10-26 | — | — | US | disclosed |
| WO-2006073361-A1 | NOVEL PYRIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2006-07-13 | — | — | WO | disclosed |
| EP-1575947-A1 | 2-OXOPYRIDIN-3-YL THIA(DI)AZOLE DERIVATIVES FOR USE IN THE TREATMENT OF CELL PROLIFERATION AND APOPTOSIS RELATED DISEASES | Amgen Inc. (US) | 2005-09-21 | — | — | EP | disclosed |
| WO-2005040127-A1 | NOVEL COMPOUNDS AS AGONIST FOR PPAR GAMMA AND PPAR ALPHA, METHOD FOR PREPARATION OF THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | LG LIFE SCIENCES LTD. (KR) | 2005-05-06 | — | — | WO | disclosed |
| US-20040147561-A1 | Pyrid-2-one derivatives and methods of use | SYNGENTA CROP PROTECTION AG (CH) | 2004-07-29 | — | — | US | disclosed |
| WO-2004060890-A1 | 2-OXOPYRIDIN-3-YL THIA (DI) AZOLE DERIVATES FOR USE IN THE TREATMENT OF CELL PROLIFERATION AND APOPTOSIS RELATED DISEASES | AMGEN INC. (US) | 2004-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10544145-B2 | P2X3 and/or P2X2/3 compounds and methods | P2RX3, P2RX2, P2RX1 | CYP2C9 1862/4885NPSR1 115/4885GLO1 3682/4885 |
| US-20230219954-A1 | P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS | P2RX3, P2RX2, P2RX1 | CYP2C9 1862/4885NPSR1 115/4885GLO1 3682/4885 |
| US-10550102-B2 | Indane and indoline derivatives and the use thereof as soluble guanylate cyclase activators | GUCY1A2, GUCY1A1, PDE3A | CYP2C9 673/4885NPSR1 1077/4885GLO1 658/4885 |
| US-10590127-B2 | P2X3 and/or P2X2/3 compounds and methods | P2RX3, P2RX2, P2RX1 | CYP2C9 1826/4885NPSR1 198/4885GLO1 2803/4885 |
| US-20040147561-A1 | Pyrid-2-one derivatives and methods of use | PLPBP, PNPO, PDXK | CYP2C9 344/4885NPSR1 3531/4885GLO1 921/4885 |
| US-20060241151-A1 | Pyrid-2-one derivatives and methods of use | PLPBP, PNPO, PDXK | CYP2C9 309/4885NPSR1 3457/4885GLO1 1002/4885 |
| US-20200109143-A1 | P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS | P2RX3, P2RX2, P2RX1 | CYP2C9 1862/4885NPSR1 115/4885GLO1 3682/4885 |
| US-20190119254-A1 | INDANE AND INDOLINE DERIVATIVES AND THE USE THEREOF AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | GUCY1A2, GUCY1A1, PDE3A | CYP2C9 673/4885NPSR1 1077/4885GLO1 658/4885 |
| US-11685736-B2 | P2X3 and/or P2X2/3 compounds and methods | P2RX3, P2RX2, P2RX1 | CYP2C9 1862/4885NPSR1 115/4885GLO1 3682/4885 |
| US-20190248789-A1 | P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS | P2RX3, P2RX2, P2RX1 | CYP2C9 1862/4885NPSR1 115/4885GLO1 3682/4885 |
| US-10316039-B2 | P2X3 and/or P2X2/3 compounds and methods | P2RX3, P2RX2, P2RX1 | CYP2C9 1862/4885NPSR1 115/4885GLO1 3682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.